Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial

Debu Tripathy*, M. Lichinitzer, A. Lazarev, S. A. MacLachlan, J. Apffelstaedt, M. Budde, B. Bergstrom, E. Abdi, N. Abramson, T. M. Baker, L. W. Kirkegaard, J. R. Schmidt, D. Bell, R. Bell, R. J. Belt, J. I. Bernstein, R. G. Just, R. A. Burningham, B. Trafficante, V. CaggianoT. Cartwright, I. N. Chernozemsky, P. Clingan, P. Conkling, J. B. Craig, A. B. Grosbach, D. Decker, E. Dickman, W. Dugan, W. Dunlap, P. D. Eisenberg, J. Ellerton, M. Ettinger, F. Ey, G. Falkson, C. Falkson, K. Fink, J. Fleagle, T. Forlenza, V. A. Gorbunova, G. E. Gross, T. Grotes, J. Grygiel, A. Gudgeon, I. D. Werner, D. Hacking, G. W. Harrer, V. Harvey, R. Hirsch, A. Koletsky, J. P. Jordaan, D. Kaye Cash, R. Sh Khasanov, J. A. LaFata, S. LaFollette, P. Koshla, G. Landers, H. C. Lebos, J. Lloyd Wade, T. Lowenthal, R. Lyons, S. A. McLachlan, R. Murray, D. Perez, K. Phadke, B. Rapoport, P. G. Rausch, B. Robinson, G. Sarna, A. Saven, M. Schwartz, V. F. Semiglazov, J. Stewart, K. Sunderland, L. Thomas, C. L. Vogel, M. Martinez-Rio, D. A. Vorobiof, S. Wilks, P. Woolley

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

74 Scopus citations

Abstract

Background: We report the first results of a randomized trial assessing a new oral aminobisphosphonate, ibandronate, in patients with bone metastases from breast cancer. Patients and methods: Patients (n = 435) received placebo, or oral ibandronate 20 mg or 50 mg once-daily for 96 weeks. The primary efficacy measure was the number of 12-week periods with new bone complications [skeletal morbidity period rate (SMPR)]. Multivariate Poisson regression analysis assessed the relative risk reduction of skeletal-related events. Secondary efficacy analyses included bone pain and analgesic use. Adverse events were monitored. Results: SMPR was significantly reduced with oral ibandronate [placebo 1.2, 20 mg group 0.97 (P = 0.024), 50 mg group 0.98 (P = 0.037)]. Ibandronate 50 mg significantly reduced the need for radiotherapy (P = 0.005 versus placebo). The relative risk of skeletal events was reduced by 38% (20 mg dose) and 39% (50 mg dose) versus placebo (P = 0.009 and P = 0.005). The tolerability profile of ibandronate was similar to placebo. Conclusions: Oral ibandronate is an effective and well-tolerated treatment for metastatic bone disease. The 50 mg dose is being further evaluated in clinical trials, and this dose was recently approved in the European Union for the prevention of skeletal events in patients with breast cancer and bone metastases.

Original languageEnglish (US)
Pages (from-to)743-750
Number of pages8
JournalAnnals of Oncology
Volume15
Issue number5
DOIs
StatePublished - May 2004

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this